mTOR作为抗癌靶点在泌尿系统肿瘤治疗中的研究进展  

mTOR inhibition as a therapeutic strategy in the management of urologic malignancies

作　　者：何春锋[1] 崔心刚[1] 

机构地区：[1]上海长征医院泌尿外科,上海200003

出　　处：《中国癌症杂志》2011年第10期816-820,共5页China Oncology

摘　　要：哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)能调节蛋白合成,细胞生长和凋亡。针对雷帕霉素抗肿瘤机制的研究表明,很多实质性肿瘤细胞中mTOR均高表达,包括泌尿系统肿瘤,如前列腺癌,膀胱癌和肾癌。前列腺癌和膀胱癌的体外、体内实验证实了mTOR信号通路在调控肿瘤侵袭和转移中的重要性。雷帕霉素及其类似物西罗莫司(temsirolimus,CCI2779)和依维莫司(everolimus,RAD001)都有明确的抗肿瘤作用。治疗前列腺癌和膀胱癌的研究已经进入临床试验阶段。在肾癌的研究中,temsirolimus已经进入临床Ⅱ及Ⅲ阶段。本文针对mTOR作为抗癌靶点在泌尿系统肿瘤治疗中的研究进展作一综述。The mammalian target of rapamycin（mTOR） is a protein kinase that regulates protein translation, cell growth,and apoptosis.Recently,there has been an enormous increase in our understanding on molecular mechanisms underlying the therapeutics of rapamycin in cancer.Alterations in the pathway regulating mTOR occur in many solid malignancies including prostate,bladder,and kidney cancer,in vitro and in vivo models of prostate and bladder cancer have established the importance of the mTOR pathway in control of cancer progression and metastasis. Temsirolimus（Torisel） and everolimus（RAD-001）,two ester analogues of rapamycin,as well as rapamycin itself have clear antitumor activity of in vitro and in vivo models and are under clinical trial investigations for prostate and bladder cancer.PhaseⅡandⅢtrials have already established the clinical efficacy of temsirolimus in renal cancer.Now we summarized the progress of the research on mTOR inhibition as a therapeutic strategy in the management of urologic malignancies.

关 键 词：哺乳动物雷帕霉素靶蛋白 抗癌靶点 泌尿系统 肿瘤 

分 类 号：R737.1[医药卫生—肿瘤]